DNA study of M. avium in lung infection
Part of Infections, Lungs & breathing clinical trials.
This study looks at the DNA of the bacteria causing your lung infection (Mycobacterium avium) to understand treatment better. It involves analyzing stored samples and may include patients who have been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been living in Ontario without moving away for the past 5 years.
- You have a lung infection caused by a bacteria called Mycobacterium avium (NTM lung disease).
- You have a stored sample of the bacteria from before you started treatment (available at a lab in Ontario).
- You are able to cough up sputum (phlegm) or can have it brought up with a special salty mist treatment.
- You do not have HIV, cystic fibrosis, a history of organ transplant, or a cavity in your lung larger than 3 cm.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will look at people with a lung infection called nontuberculous mycobacterial lung disease to find out more about how their immune system reacts. If you have this condition, your medical history and possibly a lung sample can help researchers understand why some people get sicker than others.
This trial studies how much medicine is needed (based on lab results) to treat MAC lung disease, an infection in the lungs. If you already have MAC and are receiving the recommended core antibiotics, your care may help researchers link treatment details to lab measurements.
This study looks at how NTM bacteria spread among people. If you have had a positive NTM test from your lungs, you may be able to help by sharing a sample for research.
This study tests whether a single dose of the BCG vaccine (a live vaccine used for TB) can help the immune system fight MAC lung disease. Participants must not be on MAC treatment now, but may start it during the study if needed.
This study checks whether a blood test called soluble programmed death-1 can help predict how nodular-bronchiectatic nontuberculous mycobacterial (NTM) lung disease will progress. Results may help doctors monitor patients more accurately and decide when to treat or follow more closely.
This study follows people with a newly diagnosed MAC lung infection (a specific type of mycobacterial disease) and tests how they do on the standard three-drug treatment plan. It may help researchers better understand outcomes and safety for this condition.
Hear when a new Mycobacterium Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.